Diagnosis and therapy of tacrolimus toxicity in a liver transplant recipient during COVID-19 treatmentOA
To the Editor:SARS-CoV-2,the pathogen responsible for the pandemic of coronavirus disease 2019(COVID-19),has had profound impacts on human health,and its antagonist Paxlovid is a commonly used treatment option[1].However,treatment selection for immunosuppressed patients,such as liver recipients,remains uncertain due to potential drug interactions and the risk of immunosuppressant dosage adjustment,which can cause liver injury[2].
Feng Zhu;Yi-Ming Wang;Ming Ni;Yuan Liang;Jie-Hui Huang;Xue-Hao Wang;Feng Cheng;Ling Lu;
Hepatobiliary Center,The First Affiliated Hospital of Nanjing Medical University,Key Laboratory of Liver Transplantation,Chinese Academy of Medical Sciences,NHC Key Laboratory of Liver Transplantation,Research Unit of Liver Transplantation and Transplant Immunology,Chinese Academy of Medical Sciences,Nanjing 210000,China Department of Respiratory and Critical Care Medicine,Wuxi Fifth People’s Hospital,Wuxi 214000,ChinaHepatobiliary Center,The First Affiliated Hospital of Nanjing Medical University,Key Laboratory of Liver Transplantation,Chinese Academy of Medical Sciences,NHC Key Laboratory of Liver Transplantation,Research Unit of Liver Transplantation and Transplant Immunology,Chinese Academy of Medical Sciences,Nanjing 210000,ChinaDepartment of Respiratory and Critical Care Medicine,Wuxi Fifth People’s Hospital,Wuxi 214000,ChinaHepatobiliary Center,The First Affiliated Hospital of Nanjing Medical University,Key Laboratory of Liver Transplantation,Chinese Academy of Medical Sciences,NHC Key Laboratory of Liver Transplantation,Research Unit of Liver Transplantation and Transplant Immunology,Chinese Academy of Medical Sciences,Nanjing 210000,China Jiangsu Key Laboratory of Cancer Biomarkers,Prevention and Treatment,Collaborative Innovation Center for Cancer Personalized Medicine,Nanjing Medical University,Nanjing 210000,China
临床医学
dosagetreatmentantagonist
《Hepatobiliary & Pancreatic Diseases International》 2024 (003)
P.326-330 / 5
The study was supported by grants from the National Natural Science Foundation of China(81871259,81971495,82070675,81530048,82200731 and 81570562);the Foundation of Jiangsu Collaborative Innovation Center of Biomedical Functional Materials,and the Priority Academic Program Development of Jiangsu Higher Education Institutions.
评论